Compare Crowdstrike Holdings Inc (CRWD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Novavax Inc — how do they compare? Crowdstrike Holdings Inc trades at $221.69 (market cap $225.95B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: Crowdstrike Holdings Inc is far larger — about 172.5× Novavax Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| CRWD | NVAX | |
|---|---|---|
Market Cap | $225.95B | $1.31B |
Sector | Technology | Health |
52-Week High | $225.16 | $11.19 |
52-Week Low | $87.56 | $6.22 |
Enterprise Value | $222.22B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $221.85, down 1.47% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. Revenue growth remains strong, reaching $3.95 billion in 2025, though net income margins are negative. Recent news highlights leadership in cybersecurity and AI-driven threat detection, with the stock up 106% over six months. A 1:4 stock split occurred on July 2, 2026.
The stock offers growth exposure to cybersecurity demand, supported by analyst optimism and platform consolidation, but carries high valuation multiples and profitability risks. Upside depends on sustained revenue expansion and margin improvement, while volatility and competitive pressures pose challenges.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
